RU94046424A - Способ разделения форм днказы, днказа человека, фармацевтическая композиция, способ хранения днказы, способ лечения - Google Patents

Способ разделения форм днказы, днказа человека, фармацевтическая композиция, способ хранения днказы, способ лечения

Info

Publication number
RU94046424A
RU94046424A RU94046424/13A RU94046424A RU94046424A RU 94046424 A RU94046424 A RU 94046424A RU 94046424/13 A RU94046424/13 A RU 94046424/13A RU 94046424 A RU94046424 A RU 94046424A RU 94046424 A RU94046424 A RU 94046424A
Authority
RU
Russia
Prior art keywords
ase
dna
separation
components
forms
Prior art date
Application number
RU94046424/13A
Other languages
English (en)
Other versions
RU2238320C2 (ru
Inventor
Френз Джон
Us]
Лж.Шайр Стивен
Б.Сливковски Мэри
Original Assignee
Генентек
Генентек, Инк.
Инк. (US)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Генентек, Генентек, Инк., Инк. (US) filed Critical Генентек
Publication of RU94046424A publication Critical patent/RU94046424A/ru
Application granted granted Critical
Publication of RU2238320C2 publication Critical patent/RU2238320C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y10S435/815—Enzyme separation or purification by sorption

Abstract

Изобретения относится к идентификации и характеристике двух компонентов рекомбинантного препарата ДНКазы. Эти компоненты представляют собой очищенную дезаминированную и очищенную недезаминированную человечускую ДНКазу. В изобретении изучены способы разделения этих компонентов и использования для фармацевтических целей недезаминированного вида, особенно в составе композиций, когда эти формы помещены в пластиковые ампулы, для введения пациентам, страдающим от нарушений легочного характера.

Claims (1)

  1. Изобретения относится к идентификации и характеристике двух компонентов рекомбинантного препарата ДНКазы. Эти компоненты представляют собой очищенную дезаминированную и очищенную недезаминированную человечускую ДНКазу. В изобретении изучены способы разделения этих компонентов и использования для фармацевтических целей недезаминированного вида, особенно в составе композиций, когда эти формы помещены в пластиковые ампулы, для введения пациентам, страдающим от нарушений легочного характера.
RU94046424A 1992-06-08 1993-05-28 Способ разделения смеси человеческой днказы (варианты), очищенная дезамидированная человеческая днказа, очищенная недезамидированная человеческая днказа, фармацевтическая композиция для снижения вязкоупругости гноя (варианты), способ лечения пациента, страдающего скоплением гноя (варианты), способ лечения пациента, страдающего муковисцидозом, бронхитом, пневмонией RU2238320C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/895,300 1992-06-08
US07/895,300 US5279823A (en) 1992-06-08 1992-06-08 Purified forms of DNASE

Publications (2)

Publication Number Publication Date
RU94046424A true RU94046424A (ru) 1997-03-10
RU2238320C2 RU2238320C2 (ru) 2004-10-20

Family

ID=25404292

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94046424A RU2238320C2 (ru) 1992-06-08 1993-05-28 Способ разделения смеси человеческой днказы (варианты), очищенная дезамидированная человеческая днказа, очищенная недезамидированная человеческая днказа, фармацевтическая композиция для снижения вязкоупругости гноя (варианты), способ лечения пациента, страдающего скоплением гноя (варианты), способ лечения пациента, страдающего муковисцидозом, бронхитом, пневмонией

Country Status (30)

Country Link
US (4) US5279823A (ru)
EP (2) EP1013284B1 (ru)
JP (1) JP3383307B2 (ru)
KR (2) KR100323357B1 (ru)
AT (2) ATE195340T1 (ru)
AU (1) AU682822B2 (ru)
BG (1) BG62335B1 (ru)
BR (1) BR9306670A (ru)
CA (1) CA2137237C (ru)
CZ (1) CZ293105B6 (ru)
DE (3) DE4392749T1 (ru)
DK (1) DK0644932T3 (ru)
ES (1) ES2150447T3 (ru)
FI (1) FI945549A0 (ru)
GB (1) GB2282140B (ru)
GE (1) GEP20002300B (ru)
GR (1) GR3034718T3 (ru)
HU (1) HU219549B (ru)
IL (1) IL105724A (ru)
MD (1) MD960288A (ru)
NO (1) NO318644B1 (ru)
NZ (1) NZ253559A (ru)
PL (1) PL175873B1 (ru)
PT (1) PT644932E (ru)
RO (1) RO117188B1 (ru)
RU (1) RU2238320C2 (ru)
SK (1) SK282957B6 (ru)
TJ (1) TJ396B (ru)
UA (1) UA46693C2 (ru)
WO (1) WO1993025670A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2550277C2 (ru) * 2009-07-21 2015-05-10 Биотек Фармакон АСА Способ удаления загрязняющей нуклеиновой кислоты из реакций обратной транскрипции и амплификации

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449968B1 (en) * 1988-12-23 1999-02-24 Genentech, Inc. Process for the preparation of human dnase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
EP0748225B1 (en) * 1994-03-04 2004-06-09 Genentech, Inc. PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION
WO1995023854A1 (en) * 1994-03-04 1995-09-08 Genentech, Inc. IMPROVED DNase LIQUID SOLUTIONS
EP0817839A1 (en) * 1994-05-05 1998-01-14 Human Genome Sciences, Inc. Human dnase
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
US6251648B1 (en) 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
US5602110A (en) * 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
DE69522799T2 (de) * 1994-09-06 2002-06-20 Seiichi Tanuma Neuartige desoxyribonuklease
US5863563A (en) * 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
DE69736276T2 (de) * 1996-02-05 2007-08-30 Genentech Inc., San Francisco Menschliche dnase resistent gegen actininhibitoren
US6482626B2 (en) * 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
CN103641885A (zh) * 1998-05-06 2014-03-19 基因技术股份有限公司 用离子交换层析纯化蛋白质
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
AU3500901A (en) * 2000-02-11 2001-08-20 Medic Aid Ltd Drug delivery apparatus
US6767699B2 (en) 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
MD20010375A (ru) * 2001-11-19 2003-06-30 АНДРИЕВСКИ Сергей Смеситель
MD2260C2 (ru) * 2001-11-22 2004-03-31 АНДРИЕВСКИ Сергей Смеситель
CA2496060C (en) 2002-09-11 2015-08-04 Genentech, Inc. Protein purification by ion exchange chromatography
US7067298B2 (en) 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US7595179B2 (en) 2004-04-19 2009-09-29 Applied Biosystems, Llc Recombinant reverse transcriptases
US20080160577A1 (en) * 2005-02-04 2008-07-03 Glaxo Group Limited Optimization of Heterologous Polypeptide Expression
KR100655438B1 (ko) * 2005-08-25 2006-12-08 삼성전자주식회사 자기 기억 소자 및 그 형성 방법
US20080044851A1 (en) * 2006-06-02 2008-02-21 Epicentre Technologies Compositions and methods for removal of DNA from a sample
RU2009118359A (ru) * 2006-10-18 2010-11-20 Перинесс Лтд. (Il) Способ и фармацевтическая композиция для диагностики и лечения недостаточности репродуктивной функции у мужчин
EP3441402A1 (en) 2007-10-30 2019-02-13 Genentech, Inc. Antibody purification by cation exchange chromatography
WO2009123950A2 (en) * 2008-03-31 2009-10-08 The Trustees Of The University Of Pennsylvania Chimera comprising bacterial cytotoxin and methods of using the same
EP3318635A1 (en) 2011-04-21 2018-05-09 University of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
EP2809780B1 (en) * 2012-02-01 2018-05-02 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
CN103920144B (zh) * 2013-01-15 2016-09-14 吴庄民 重组人的脱氧核糖核酸酶i的新应用
CN106794392A (zh) 2014-06-25 2017-05-31 喜康生技公司 用于纯化蛋白质的方法和试剂
JP6071018B2 (ja) 2014-10-31 2017-02-01 Ｊｃｒファーマ株式会社 組換えヒトＤＮａｓｅＩの製造方法
CA2988471A1 (en) * 2015-07-28 2017-02-02 University Of Massachusetts Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
CA3012344A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
TWI826360B (zh) 2016-11-17 2023-12-21 美商艾歐凡斯生物治療公司 殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
EP4157309A1 (en) 2020-06-01 2023-04-05 Black Cat Bio Limited Compositions and methods for treating infections and netopathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801956A (en) * 1954-08-24 1957-08-06 Merck & Co Inc Process for preparing pancreatic desoxyribonuclease
US2834710A (en) * 1955-06-29 1958-05-13 Merck & Co Inc Pancreatic desoxyribonuclease penicillin composition and process of preparation
US3208908A (en) * 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US3663690A (en) * 1969-08-12 1972-05-16 Hoechst Co American Mucolytic composition and method of treatment of broncho-pulmonary disorders therewith
CA1059937A (en) * 1975-03-25 1979-08-07 Boen T. Khouw Isolation and purification of deoxyribonuclease
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
EP0449968B1 (en) * 1988-12-23 1999-02-24 Genentech, Inc. Process for the preparation of human dnase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2550277C2 (ru) * 2009-07-21 2015-05-10 Биотек Фармакон АСА Способ удаления загрязняющей нуклеиновой кислоты из реакций обратной транскрипции и амплификации

Also Published As

Publication number Publication date
ES2150447T3 (es) 2000-12-01
EP0644932B1 (en) 2000-08-09
GB2282140A (en) 1995-03-29
TJ396B (en) 2004-12-29
DE69334317D1 (de) 2010-03-11
CA2137237C (en) 2004-10-26
BR9306670A (pt) 1998-12-08
HU9403512D0 (en) 1995-02-28
MD960288A (ru) 1998-01-31
DE69329200D1 (de) 2000-09-14
NZ253559A (en) 1996-11-26
BG99234A (bg) 1995-07-28
US6440412B1 (en) 2002-08-27
IL105724A (en) 1997-06-10
NO944752D0 (no) 1994-12-08
RU2238320C2 (ru) 2004-10-20
AU4398193A (en) 1994-01-04
GB9423695D0 (en) 1995-01-11
BG62335B1 (bg) 1999-08-31
HU219549B (hu) 2001-05-28
DE69329200T2 (de) 2001-04-26
DE4392749T1 (de) 1995-07-20
EP1013284B1 (en) 2010-01-20
US5783433A (en) 1998-07-21
NO944752L (no) 1994-12-08
EP1013284A3 (en) 2000-08-30
RO117188B1 (ro) 2001-11-30
UA46693C2 (uk) 2002-06-17
DK0644932T3 (da) 2001-01-02
US6932965B2 (en) 2005-08-23
IL105724A0 (en) 1993-09-22
ATE455557T1 (de) 2010-02-15
JPH07507455A (ja) 1995-08-24
CZ293105B6 (cs) 2004-02-18
EP1013284A2 (en) 2000-06-28
FI945549A (fi) 1994-11-25
PL175873B1 (pl) 1999-02-26
ATE195340T1 (de) 2000-08-15
HUT70468A (en) 1995-10-30
GEP20002300B (en) 2000-11-25
US20030077267A1 (en) 2003-04-24
AU682822B2 (en) 1997-10-23
FI945549A0 (fi) 1994-11-25
SK149594A3 (en) 1996-01-10
WO1993025670A1 (en) 1993-12-23
CZ303294A3 (en) 1995-06-14
EP0644932A1 (en) 1995-03-29
SK282957B6 (sk) 2003-01-09
PT644932E (pt) 2001-02-28
JP3383307B2 (ja) 2003-03-04
GB2282140B (en) 1996-04-17
NO318644B1 (no) 2005-04-25
CA2137237A1 (en) 1993-12-23
US5279823A (en) 1994-01-18
KR100323357B1 (ko) 2002-02-19
GR3034718T3 (en) 2001-01-31
KR100302092B1 (ko) 2001-10-22

Similar Documents

Publication Publication Date Title
RU94046424A (ru) Способ разделения форм днказы, днказа человека, фармацевтическая композиция, способ хранения днказы, способ лечения
ATE242633T1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE254926T1 (de) Verwendung eines consensus-interferons zur reduzierung der nebeneffekte in der interferon behandlung von viralen hepatiten.
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
DE9190171U1 (ru)
DE3688038T2 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
DE69131253D1 (de) Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
GEP19980954B (en) Ointment “Hypoaskane”
FR2599032B1 (fr) Nouveaux fluorophosphates simples ou mixtes d'amino-acides, leur preparation, et leur utilisation comme medicament, notamment dans le traitement des syndromes degeneratifs de l'os
IT1237119B (it) Esteri dell'acido 6-d(-)-alfa-(4-etil-2,3-diosso-1- piperazinilcarbonilamino)-alfa-fenilacetamido penicillanico, procedimento per la loro preparazione e relative composizioni farmaceutiche
ATE96150T1 (de) Thioester und dessen verwendung zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von ischaemie und von reperfusionsyndromen.